Baroda BNP Paribas Health and Wellness Fund

A Sectoral/Thematic Fund scheme from Baroda BNP Paribas Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF251K01VA5).

NAV ₹11.2298 on 16 November 2026.

Expense ratio

Total expense ratio 1.47% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 1.04%, brokerage 0.08%, transaction costs 0.00%, statutory levies including GST 0.35%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year16.3%12.9%-8.9%0.720.78

Too little NAV history for the 3, 5, 10-year figures.

Not ranked in its category: too few comparable funds have the history to rank against.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 97.0% of the portfolio.

  1. Sun Pharmaceutical Industries Limited — 8.58%
  2. Divi's Laboratories Limited — 8.41%
  3. Torrent Pharmaceuticals Limited — 7.74%
  4. Laurus Labs Limited — 7.56%
  5. IPCA Laboratories Limited — 6.06%
  6. Lupin Limited — 5.86%
  7. Apollo Hospitals Enterprise Limited — 5.58%
  8. Fortis Healthcare Limited — 4.06%
  9. Glenmark Pharmaceuticals Limited — 3.13%
  10. Clearing Corporation of India Ltd (cash (TREPS)) — 2.95%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.